ClinicalTrials.gg
CompletedNCT06744868Updated Dec 27, 2024

A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects

A Phase 1 interventional study of THDBH120 injection (SAD) and Placebo of THDBH120 injection (SAD) in Healthy, sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Dec 2023, registered Dec 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study includes single-ascending dose cohorts (SAD cohorts) and multiple-ascending dose cohorts (MAD cohorts). The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of THDBH120 injection in healthy patients.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Tonghua Dongbao Pharmaceutical Co.,Ltd is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Chinese subjects aged 18 to 45 years (inclusive), male or female;
  • (BMI) ≥ 19 kg/m2 and ≤ 28kg/m2, male weight ≥ 50 kg, females weight≥ 45 kg;
  • Normal or abnormal but not physical examination and vital signs at screening.

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of type 2 diabetes or have had episode of severe hypoglycemia;
  • Pulse rate is less than 50 bpm or more than 100 bpm at screening;
  • 12-lead with prolonged (male >450 ms, female >470 ms) or PR>200ms. Or any other situation in which a 12-lead ECG suggests a risk of ineligibility at screening;
  • A history of pancreatitis (including chronic pancreatitis or idiopathic acute pancreatitis), abnormal amylase and lipase with clinical significance or gastrointestinal injury (e.g., chronic gastritis, peptic ulcer, recurrent gastroesophageal reflux disease, cholecystitis, and gallstones) or any gastrointestinal disease that interferes with gastric emptying (e.g., gastric bypass surgery, pyloric stenosis);
  • Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2;
  • Use of SGLT inhibitors, DPP4 inhibitors, GLP-1 analogs, GLP-1 receptor agonists, and other drugs that investigators recognize may affect the study during the 3 months prior to randomization;
  • Have had a significant change in weight during the 6 months prior to screening, such as weight loss > 10%, or recent significant changes in diet or exercise habits.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    THDBH120 injection (SAD)

    Drug: THDBH120 injection (SAD)

  • Placebo comparator
    Placebo of THDBH120 injection (SAD)

    Drug: Placebo of THDBH120 injection (SAD)

  • Experimental
    THDBH120 injection (MAD)

    Drug: THDBH120 injection (MAD)

  • Placebo comparator
    Placebo of THDBH120 injection (MAD)

    Drug: Placebo of THDBH120 injection (MAD)

Interventions

  • Participants received escalating single doses of THDBH120 by subcutaneous injection.

  • DrugPlacebo of THDBH120 injection (SAD)

    Participants received single dose of placebo by subcutaneous injection.

  • Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.

  • DrugPlacebo of THDBH120 injection (MAD)

    Participants received placebo once weekly for four weeks by subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)

    Time frame: From the first drug administration to the follow-up visit (57 days after the last drug administration)

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of THDBH120.

    Time frame: Day 1 Pre-dose through Day 42 (SAD), Day 1 Pre-dose through Day 29 (MAD)

  2. Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of THDBH120

    Time frame: Day 1 Pre-dose through Day 42 (SAD), Day 1 Pre-dose through Day 29 (MAD)

  3. Evaluate the Fasting Blood Glucose (FBG ) of THDBH120

    Time frame: Day 1 Pre-dose through Day 8 (SAD), Day 1 Pre-dose through Day 29 (MAD)

  4. Number of Participants With Anti-THBHD120 Antibodies

    Time frame: From the first drug administration to the follow-up visit (57 days after the last drug administration)

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Sep 2024, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 20, 2024
StartActual
Dec 19, 2023
Primary completionActual
Sep 22, 2024
CompletionActual
Sep 22, 2024
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06744868
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Dec 19, 2023
Primary completion
Sep 22, 2024
Completion
Sep 22, 2024
Last update
Dec 27, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: THDBH120

Start the discussion